Full-year results from a pivotal phase 3 trial confirm previously reported data demonstrating ONS-5010 was well tolerated and had no unanticipated safety signals, according to a press release from Outlook Therapeutics.
NORSE TWO enrolled 228 patients with wet age-related macular degeneration at 39 sites across the U.S. to compare ONS-5010/Lytenava (bevacizumab-vikg) vs. Lucentis (ranibizumab, Genentech). The study’s primary endpoint was the proportion of patients who gained at least 15 letters in best corrected visual acuity at 11 months. Topline data demonstrated ONS-5010 met its